Form S-3 Corbus Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Corbus Pharma (CRBP) Tops Q3 EPS by 2c
November 11, 2015 7:33 AM ESTCorbus Pharma (NASDAQ: CRBP) reported Q3 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).
Expected Near-Term Milestones
Continue to screen and enroll patients in both the Phase 2 studies in CF and in systemic sclerosis to remain on track... MoreCorbus Pharma (CRBP) Files $100M Mixed Shelf
November 11, 2015 6:51 AM ESTCorbus Pharma (NASDAQ: CRBP) filed a registration with the U.S. SEC to sell up to $100 million of mixed securities.
... More